drugset
drugset / Trial / NCT03694041

Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers

NCT03694041 ↗

Phase 1 Completed 88 enrolled Aptabio Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to evaluate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of single ascending doses and multiple ascending doses of APX-115 in healthy males. This study also aims to evaluate the effect of food consumption on the pharmacokinetics of APX-115 and potential interaction between caffeine and APX-115 in healthy males.

Timeline

Start
2018-05-28
Primary completion
2019-03-06
Completion
2019-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Isuzinaxib Small molecule — —

Indications

No indication recorded.